153 related articles for article (PubMed ID: 38149251)
1. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O; Peczynski C; Boreland W; Lemaitre J; Afanasyeva K; Kornblit B; Jurado M; Martinez C; Natale A; Pérez-Simón JA; Brunello L; Avenoso D; Klein S; Ozkurt ZN; Herrera C; Wichert S; Chiusolo P; Gavriilaki E; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
Front Immunol; 2023; 14():1283034. PubMed ID: 38149251
[TBL] [Abstract][Full Text] [Related]
2. ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O; Peczynski C; Boreland W; Lemaitre J; Reinhardt HC; Afanasyeva K; Avenoso D; Holderried TAW; Kornblit BT; Gavriilaki E; Martinez C; Chiusolo P; Mico MC; Dagunet E; Wichert S; Ozdogu H; Piekarska A; Kinsella F; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
Bone Marrow Transplant; 2024 Mar; 59(3):380-386. PubMed ID: 38184740
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD).
Solh MM; Farnham C; Solomon SR; Bashey A; Morris LE; Holland HK; Zhang X
Bone Marrow Transplant; 2023 Feb; 58(2):168-174. PubMed ID: 36352015
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
Front Immunol; 2022; 13():954268. PubMed ID: 35990629
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease.
Oarbeascoa G; Lozano ML; Guerra LM; Amunarriz C; Saavedra CA; Garcia-Gala JM; Viejo A; Revilla N; Acosta Fleitas C; Arroyo JL; Martinez Revuelta E; Galego A; Hernandez-Maraver D; Kwon M; Diez-Martin JL; Pascual C;
Biol Blood Marrow Transplant; 2020 Apr; 26(4):651-658. PubMed ID: 31917270
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
13. Efficiency and Toxicity of Ruxolitinib as the Salvage Treatment in Steroid-Refractory Acute Graft-Versus-Host Disease after Haplo-Identical Stem Cell Transplantation.
Liu Y; Fan Y; Zhang W; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Transplant Cell Ther; 2021 Apr; 27(4):332.e1-332.e8. PubMed ID: 33836880
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.
Perfetti P; Carlier P; Strada P; Gualandi F; Occhini D; Van Lint MT; Ibatici A; Lamparelli T; Bruno B; Raiola AM; Dominietto A; Di Grazia C; Bregante S; Zia S; Ferrari GM; Stura P; Pogliani E; Bacigalupo A
Bone Marrow Transplant; 2008 Nov; 42(9):609-17. PubMed ID: 18660840
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature.
Yan WL; Zhao FY; Gu ME; Liu N; Guo XP; Xu XJ
Paediatr Drugs; 2023 Sep; 25(5):577-584. PubMed ID: 37284944
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT.
Meng G; Wang J; Wang X; Wang Y; Wang Z
Ann Hematol; 2020 Feb; 99(2):343-349. PubMed ID: 31879790
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib add-on in corticosteroid-refractory graft-
Dang SH; Liu Q; Xie R; Shen N; Zhou S; Shi W; Liu W; Zou P; You Y; Zhong ZD
World J Clin Cases; 2020 Mar; 8(6):1065-1073. PubMed ID: 32258077
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report.
Berger M; Pessolano R; Albiani R; Asaftei S; Barat V; Carraro F; Biasin E; Madon E; Fagioli F
J Pediatr Hematol Oncol; 2007 Oct; 29(10):678-87. PubMed ID: 17921848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]